查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1924716

核子医学和放射性药物市场（按产品类型、同位素类型、应用、最终用户和分销管道划分）—2026-2032年全球预测

Nuclear Medicine & Radiopharmaceuticals Market by Product Type, Isotope Type, Application, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，核医和放射性药物市场价值将达到 95.2 亿美元，到 2026 年将成长至 100.7 亿美元，到 2032 年将达到 151.2 亿美元，年复合成长率为 6.83%。

关键市场统计数据
基准年 2025 95.2亿美元
预计年份：2026年 100.7亿美元
预测年份 2032 151.2亿美元
复合年增长率 (%) 6.83%

本书权威地介绍了影响现代核子医学和放射性药物的技术、监管和供应链因素。

核子医学和放射性药物领域正处于快速科学创新和日益复杂的商业性趋势的交汇点。分子影像示踪剂、标靶放射性治疗药物和生产技术的进步，与临床上对精准诊断和个人化治疗方案日益增长的重视相辅相成。本文概述了日趋成熟的技术、日益严格的监管以及不断演变的供应链结构如何影响工业界、临床和研究相关人员的策略选择。

对临床、製造和监管变革融合的全面分析，这些变革将加速精准诊断和放射治疗策略的发展。

核子医学和放射性药物领域正经历多重变革，这些变革涵盖临床实践、生产製造和政策等多个方面，并正在重新定义。在临床方面，精准诊断和治疗诊断学的趋势正在加速分子特异性示踪剂和标靶放射性核种疗法的应用，促进影像专家、肿瘤学家和核医学团队之间的合作。随着研发人员优先开发兼具诊断和治疗功能的示踪剂，这种临床发展趋势正在重塑研究重点和商业化进程。

深入评估2025年关税如何重塑放射性药物产业的供应链韧性、筹资策略和采购行为。

2025年对放射性药物原料及相关医用同位素组件征收的关税对价值链、采购惯例和终端用户成本产生了多方面的影响，但并未改变诊断和治疗药物本身的临床价值。这项关税政策提高了对本地生产的重视程度，促使一些机构和生产商重新评估其迴旋加速器设备、产生器系统、前驱化学品和屏蔽组件的筹资策略。这种转变有利于那些拥有现有国内生产能力的相关人员，并鼓励对邻近区域合作伙伴和契约製造安排进行投资。

详细的细分框架，重点介绍产品类型、临床应用、最终用户概况、通路和同位素生产方法，以指南策略规划。

市场区隔分析提供了一个结构化的视角，帮助我们了解哪些治疗和诊断途径正在推动临床应用，以及哪些领域的生产投资最为有效。市场依产品类型分析，诊断和治疗放射性药物是两大主要类别。诊断放射性药物进一步细分为PET和SPECT放射性药物，其中PET放射性药物又分为F-18和Ga-68放射性药物，SPECT放射性药物则分为非Tc-99m放射性药物和Tc-99m放射性药物。治疗放射性药物进一步分为α粒子放射性药物和β粒子放射性药物。 α粒子放射性药物包括Ra-223疗法，而β粒子放射性药物包括I-131、Lu-177和Y-90疗法。

区域分析突显了美洲、欧洲、中东和非洲以及亚太地区在基础设施、法规环境和采用趋势方面的差异。

区域趋势在放射性药物的应用、生产和分销中发挥关键作用，每个区域都面临独特的机会和挑战。在美洲，PET成像技术的成熟临床应用和对放射性药物日益增长的投资，加上密集的医疗中心和研究机构网络，为先进的示踪剂测试和本地迴旋加速器的建设提供了支持。透过区域製造地和策略伙伴关係来降低跨境差异，供应链的韧性日益受到重视。

对公司能力、伙伴关係模式和生产优势进行策略评估，以确定其竞争地位和长期生存能力。

核医和放射性药物产业的公司层级发展趋势反映了一系列策略性倡议，涵盖垂直整合和专业服务等。主要企业正投资于示踪剂开发、迴旋加速器或发生器供应、放射化学专业知识以及临床分销服务的一体化能力，以确保品管并缩短患者用药时间。其他企业则专注于自身优势的细分领域，例如新型放射性核种发现、自动化放射化学模组和契约製造，以满足日益增长的学术和商业研发客户的需求。

为产业领导者提供实用建议，以协调供应链弹性、监管规划、临床整合和可扩展生产。

产业领导者若想掌握核医和放射性药物领域的成长势头，应采取切实可行的综合性优先事项，兼顾临床价值和营运韧性。首先，应透过投资双源策略来加强供应链多元化，该策略将区域迴旋加速器设施和发生器供应网路结合，以降低单点故障和关税带来的中断风险​​。其次，应透过生产能够满足不同司法管辖区要求的材料，并优先考虑协调一致的监管沟通，来简化核准流程并促进国际临床计画。

采用透明严谨的调查方法，结合专家访谈、权威二手资料和跨领域分析架构。

我们的研究途径融合了第一手和第二手调查方法，以确保对核医和放射性药物领域获得严谨且多角度的洞察。第一手研究包括对临床医生、放射性药物药剂师、供应链管理人员和监管专家进行结构化访谈，以了解现场操作挑战和应用驱动因素。此外，我们还与製造商、合约服务供应商和分销合作伙伴进行了讨论，以补充这些专家见解，从而揭示影响示踪剂供应和临床工作流程的商业性和物流因素。

简明扼要地总结了临床进展、生产方案、区域差异以及生态系统内各相关人员的策略重点。

本执行摘要指出，在临床创新、不断发展的生产技术以及不断变化的贸易和监管环境的推动下，核医学和放射性药物行业正处于转折点。诊断和治疗放射性药物正日益融入病患诊疗流程。 PET 和 SPECT 追踪剂正在改善疾病的表征，而标靶放射疗法则为难治性疾病提供了新的治疗选择。迴旋加速器生产的同位素与基于发生器的系统之间的生产方法选择，对药物的取得、物流和资金配置决策有重大影响。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：核子医学和放射性药物市场（按产品类型划分）

  • 诊断用放射性药物
    • PET放射性药物
      • F-18放射性药物
      • Ga-68放射性药物
    • SPECT放射性药物
      • 非Tc-99m放射性药物
      • 锝-99m放射性药物
  • 治疗性放射性药物
    • α粒子放射性药物
    • β射线放射性药物
      • 碘-131 (I-131)治疗方法
      • 基于钌-177 (Lu-177) 的治疗方法
      • 基于Y-90的治疗方法

9. 按同位素类型分類的核子医学和放射性药物市场

  • 迴旋加速器产生的同位素
    • C-11
    • F-18
  • 基于发生器的同位素
    • Ge-68 Ga-68 发电机
    • Mo-99 Tc-99m 产生器

第十章 核子医学和放射性药物市场（按应用领域划分）

  • 骨骼影像
  • 心臟病学
  • 发炎成像
  • 神经病学
  • 肿瘤学

第十一章 核子医学和放射性药物市场（按最终用户划分）

  • 门诊护理设施
  • 诊断影像中心
  • 医院放射科
  • 研究所

第十二章 核子医学和放射性药物市场（按分销管道划分）

  • 离线
  • 在线的

第十三章 核医与放射性药物市场（按地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 核医与放射性药物市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国核子医学与放射性药物市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国核子医学与放射性药物市场

第十七章 中国核医与放射性药物市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Advanced Accelerator Applications SA
  • AstraZeneca PLC
  • Bayer AG
  • Bracco Imaging SpA
  • Bristol-Myers Squibb Company
  • BWX Technologies, Inc.
  • Cardinal Health, Inc.
  • Clarity Pharmaceuticals Ltd.
  • Curium Pharma
  • Eckert & Ziegler SE
  • Eli Lilly and Company
  • GE HealthCare Technologies Inc.
  • Ion Beam Applications SA
  • ITM Isotope Technologies Munich SE
  • Jubilant Pharmova Limited
  • Lantheus Holdings, Inc.
  • NorthStar Medical Radioisotopes, LLC
  • Novartis AG
  • Siemens Healthineers AG
  • Telix Pharmaceuticals Limited
Product Code: MRR-7A380DA7C449

The Nuclear Medicine & Radiopharmaceuticals Market was valued at USD 9.52 billion in 2025 and is projected to grow to USD 10.07 billion in 2026, with a CAGR of 6.83%, reaching USD 15.12 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 9.52 billion
Estimated Year [2026] USD 10.07 billion
Forecast Year [2032] USD 15.12 billion
CAGR (%) 6.83%

An authoritative introduction that contextualizes technological, regulatory, and supply chain forces shaping contemporary nuclear medicine and radiopharmaceuticals

The landscape of nuclear medicine and radiopharmaceuticals stands at the intersection of rapid scientific innovation and increasingly complex commercial dynamics. Advances in molecular imaging tracers, targeted radiotherapeutics, and production technologies have converged with a heightened clinical emphasis on precision diagnostics and personalized treatment pathways. This introduction sets the stage for how technological maturation, tighter regulatory scrutiny, and evolving supply chain architectures are influencing strategic choices across industry, clinical, and research stakeholders.

Diagnostic radiopharmaceuticals continue to expand their clinical reach as PET and SPECT tracers deliver higher-resolution disease characterization, while therapeutic radiopharmaceuticals are gaining traction for targeted oncology indications where conventional modalities have limitations. Concurrently, production paradigms that include cyclotron-produced isotopes and generator-based supply chains are recalibrating site-of-care logistics and vendor relationships. Regulatory frameworks are adapting to novel radiopharmaceutical modalities, balancing expedited patient access with stringent safety and manufacturing quality expectations.

As stakeholders navigate this evolving ecosystem, an integrated perspective that considers clinical utility, manufacturing resilience, regulatory pathways, and commercial scalability is essential. This introduction provides a framework for the sections that follow, focusing on transformative market shifts, tariff-driven trade implications, segmentation-based insights, and regionally differentiated strategies that together inform high-impact decision-making.

A comprehensive analysis of converging clinical, manufacturing, and regulatory shifts that are accelerating precision diagnostics and radiotherapeutic strategies

Several transformative shifts are redefining nuclear medicine and radiopharmaceuticals, and they operate across clinical practice, manufacturing, and policy domains. Clinically, the move toward precision diagnostics and theranostics is accelerating adoption of molecularly specific tracers and targeted radionuclide therapies, driving collaborations between imaging specialists, oncologists, and nuclear medicine teams. This clinical momentum is in turn shaping research priorities and commercial pipelines as developers prioritize tracers that enable both diagnosis and therapy pairing.

On the manufacturing front, decentralization is gaining traction; hospitals and regional centers are investing in on-site cyclotrons and radiochemistry suites to reduce lead times for short-lived isotopes while also forming partnerships with contract manufacturing organizations for complex radiotherapeutics. Generator-based supply chains remain critical for broader accessibility, particularly in settings where cyclotron infrastructure is impractical. Regulatory evolution is another inflection point, with agencies working to harmonize quality expectations for novel radionuclides and streamline pathways that maintain safety without unduly delaying patient access.

Finally, the commercial landscape is experiencing strategic consolidation and cross-sector partnerships that bring radiochemistry expertise, supply chain scale, and clinical distribution networks together. These shifts are not isolated; rather, they compound one another, creating an environment in which nimble organizations that align clinical value, manufacturing reliability, and regulatory foresight will capture the greatest strategic advantage.

A nuanced evaluation of how 2025 tariff measures reshaped supply chain resilience, sourcing strategies, and procurement behaviors across the radiopharmaceutical sector

The introduction of tariffs affecting radiopharmaceutical inputs and related medical isotope components in 2025 created layered effects across supply chains, procurement practices, and end-user costs without altering the underlying clinical value of diagnostic and therapeutic agents. Tariff policy increased the operational emphasis on localized production, prompting some institutions and producers to reassess sourcing strategies for cyclotron equipment, generator systems, precursor chemicals, and shielding components. This reorientation favored stakeholders with existing domestic manufacturing capabilities and incentivized investments in near-shore partners and contract manufacturing arrangements.

Procurement teams responded by diversifying supplier portfolios and negotiating long-term agreements that absorb tariff volatility, while clinical operations implemented tighter inventory management for short-lived isotopes to mitigate disruptions. The indirect cost effects were felt across distribution channels, with direct-sales models gaining attractiveness for large institutional buyers seeking single-vendor accountability and bundled service agreements that reduce administrative complexity. At the same time, smaller diagnostic centers and research organizations relied more heavily on regional distributors and generator-based isotopes to preserve clinical continuity.

Policy uncertainty also accelerated conversations on regulatory and trade harmonization for medical isotopes, as stakeholders recognized that predictable cross-border flows are essential for maintaining access to specialized tracers. In sum, tariffs acted as a catalyst for supply chain resilience investments and strategic sourcing decisions that will influence procurement and operational models going forward.

An in-depth segmentation framework that delineates product types, clinical applications, end-user profiles, channels, and isotope production modalities to guide strategy

Segmentation analysis provides a structured lens to understand which therapeutic and diagnostic pathways are driving clinical adoption and where manufacturing investments are most productive. The market is studied across Product Type with Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals as primary categories; Diagnostic Radiopharmaceuticals further differentiate into PET Radiopharmaceuticals and SPECT Radiopharmaceuticals, where PET subdivides into F-18 Radiopharmaceuticals and Ga-68 Radiopharmaceuticals, and SPECT separates into Non Tc-99m Radiopharmaceuticals and Tc-99m Radiopharmaceuticals. Therapeutic Radiopharmaceuticals are further parsed into Alpha Emitting Radiopharmaceuticals and Beta Emitting Radiopharmaceuticals, with Alpha Emitting Radiopharmaceuticals including Ra-223 Therapies and Beta Emitting Radiopharmaceuticals encompassing I-131 Based Therapies, Lu-177 Based Therapies, and Y-90 Based Therapies.

When viewed by Application, the analysis considers Bone Imaging, Cardiology, Inflammation Imaging, Neurology, and Oncology, unpacking clinical adoption drivers and reimbursement dynamics unique to each therapeutic area. End User segmentation examines Ambulatory Care Facilities, Diagnostic Imaging Centers, Hospital Radiology Departments, and Research Organizations, which differ in capital intensity, in-house radiochemistry capacity, and procurement sophistication. Distribution Channel segmentation contrasts Direct Sales, Indirect Sales, and Online Channels to reveal where integrated service models or distributor networks provide competitive advantage. Finally, Isotope Type segmentation highlights the operational distinctions between Cyclotron Produced Isotopes and Generator Based Isotopes, with cyclotron-produced isotopes further identified as C-11 and F-18 and generator-based isotopes described through Ge-68 Ga-68 Generators and Mo-99 Tc-99m Generators, underscoring how production technology influences logistics, tracer half-life management, and access across clinical settings.

Taken together, these segmentation layers illuminate which product-development priorities, production investments, and commercial channels align with clinical needs and operational realities, providing a roadmap for targeted strategy and resource allocation.

A regional analysis revealing differentiated infrastructure, regulatory environments, and adoption trajectories across Americas, Europe, Middle East & Africa, and Asia-Pacific

Regional dynamics play a pivotal role in shaping the adoption, production, and distribution of radiopharmaceuticals, and each geography presents distinct opportunities and constraints. In the Americas, established clinical adoption of PET imaging and growing investment in radiotherapeutics coincide with a dense network of tertiary care centers and research institutions, supporting advanced tracer trials and on-site cyclotron installations. Supply chain resilience is increasingly addressed through regional manufacturing hubs and strategic partnerships to mitigate cross-border volatility.

Europe, Middle East & Africa features heterogeneous regulatory environments and infrastructure maturity, where leading healthcare systems support advanced theranostic programs while many regions rely on generator-based isotopes to expand access in lower-capacity settings. Collaboration across national regulatory authorities and pan-regional networks is instrumental for harmonizing quality standards and enabling cross-border clinical trials. In the Asia-Pacific region, robust capital investment, accelerated adoption of new imaging technologies, and large patient populations are driving rapid clinical uptake, while significant public and private investment in cyclotron infrastructure and radiopharmacy capacity is expanding local production capabilities.

Across all regions, local policy, reimbursement frameworks, and clinical guidelines materially influence which isotopes and modalities gain traction. Stakeholders should therefore craft region-specific strategies that align production investments, regulatory engagement, and distribution models with the distinct clinical and infrastructure profiles of each geography.

A strategic appraisal of company capabilities, partnership models, and production strengths that determine competitive positioning and long-term viability

Company-level dynamics within nuclear medicine and radiopharmaceuticals reflect a broad array of strategic approaches, ranging from vertical integration to specialized service provision. Leading organizations are investing in integrated capabilities that combine tracer development, cyclotron or generator supply, radiochemistry expertise, and clinical distribution services to control quality and shorten time-to-patient. Others are focusing on niche strengths such as novel radionuclide discovery, automated radiochemistry modules, or contract manufacturing to serve a growing base of academic and commercial developers.

Partnerships between pharmaceutical developers, imaging device manufacturers, and clinical networks are increasingly common as stakeholders seek to align tracer innovation with clinical validation pathways and reimbursement strategies. Companies that can demonstrate robust manufacturing quality systems, validated cold-chain logistics, and scalable radiopharmacy operations command strategic advantage when negotiating supply agreements with large hospital systems and imaging networks. At the same time, smaller agile firms are capitalizing on early-stage collaboration opportunities with academic centers to advance novel tracers through proof-of-concept studies.

Competitive differentiation often hinges on the ability to secure reliable isotope supply, demonstrate regulatory compliance across jurisdictions, and support customers with turnkey services spanning authorization, logistics, and clinical trial support. For investors and partners, assessing a company's depth in production technology, regulatory expertise, and clinical engagement offers a pragmatic lens into its long-term viability and strategic fit.

A pragmatic set of actionable recommendations that align supply resilience, regulatory planning, clinical integration, and scalable manufacturing for industry leaders

Industry leaders seeking to capitalize on the momentum in nuclear medicine and radiopharmaceuticals should pursue a set of actionable, integrated priorities that balance clinical value with operational resiliency. First, strengthen supply chain diversification by investing in dual-source strategies that combine local cyclotron capacity with regional generator networks to mitigate single-point failures and tariff-induced disruptions. Second, prioritize harmonized regulatory engagement by building dossiers that anticipate cross-jurisdictional requirements, enabling smoother approvals and facilitating international clinical programs.

Third, accelerate clinical integration by partnering with hospitals and specialist centers to co-develop tracer pathways and to generate real-world evidence that supports reimbursement dialogues. Fourth, adopt scalable manufacturing platforms and validated quality systems that enable rapid scale-up of promising radiotherapeutics while maintaining compliance and traceability. Fifth, enhance commercial models by offering bundled service agreements-combining supply, onsite training, and logistics-to reduce friction for institutional buyers and to differentiate from commodity suppliers.

Finally, invest in workforce development and radiopharmacy training to ensure that facilities adopting advanced tracers have competent staff to manage complex radiochemical preparations and safety protocols. Taken together, these recommendations create a roadmap for organizations to deliver clinical impact while building resilient, growth-ready operations.

A transparent and rigorous research methodology combining expert primary interviews, authoritative secondary sources, and cross-segmentation analytical frameworks

The research approach integrates primary and secondary methods designed to ensure rigorous, triangulated insights into nuclear medicine and radiopharmaceuticals. Primary research included structured interviews with clinicians, radiopharmacists, supply chain managers, and regulatory specialists to capture frontline operational challenges and adoption drivers. These expert perspectives were complemented by discussions with manufacturers, contract service providers, and distribution partners to surface commercial and logistics considerations that influence tracer availability and clinical workflows.

Secondary research drew on peer-reviewed literature, regulatory guidance documents, clinical trial registries, and publicly available technical standards to ground findings in validated scientific and policy sources. Data synthesis employed cross-segmentation analysis to map Product Type, Application, End User, Distribution Channel, and Isotope Type against regional infrastructure and regulatory realities. Analytical rigor was ensured through methodical cross-checking of interview insights with publicly documented approvals, manufacturing practices, and clinical guidelines.

Where appropriate, sensitivity analysis was applied to assess operational risk drivers such as isotope half-life constraints, cold-chain logistics, and dependency on specialized precursor materials. Together, these methodological elements enable a robust understanding of both the clinical and commercial levers that shape strategy and investment decisions in the sector.

A concise conclusion synthesizing clinical advances, production choices, regional differentiation, and strategic priorities for stakeholders across the ecosystem

This executive synthesis underscores that nuclear medicine and radiopharmaceuticals are at an inflection point driven by clinical innovation, production technology evolution, and evolving trade and regulatory landscapes. Diagnostic and therapeutic radiopharmaceuticals are increasingly integrated into patient care pathways, with PET and SPECT tracers improving disease characterization and targeted radiotherapies offering alternative options for difficult-to-treat conditions. Production modality choices between cyclotron-produced isotopes and generator-based systems materially influence access, logistics, and capital allocation decisions.

Supply chain resilience, shaped by recent tariff dynamics and broader geopolitical considerations, is now a core strategic imperative. Organizations that proactively align manufacturing capabilities, regulatory engagement, and clinical partnerships will be best positioned to translate scientific promise into clinical impact. Regional differentiation further underscores the need for tailored approaches that respect local infrastructure, reimbursement environments, and regulatory expectations. Collectively, these insights provide a practical foundation for leaders to make informed decisions about product development priorities, manufacturing investments, and commercial partnerships as the field continues to advance.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Nuclear Medicine & Radiopharmaceuticals Market, by Product Type

  • 8.1. Diagnostic Radiopharmaceuticals
    • 8.1.1. PET Radiopharmaceuticals
      • 8.1.1.1. F-18 Radiopharmaceuticals
      • 8.1.1.2. Ga-68 Radiopharmaceuticals
    • 8.1.2. SPECT Radiopharmaceuticals
      • 8.1.2.1. Non Tc-99m Radiopharmaceuticals
      • 8.1.2.2. Tc-99m Radiopharmaceuticals
  • 8.2. Therapeutic Radiopharmaceuticals
    • 8.2.1. Alpha Emitting Radiopharmaceuticals
    • 8.2.2. Beta Emitting Radiopharmaceuticals
      • 8.2.2.1. I-131 Based Therapies
      • 8.2.2.2. Lu-177 Based Therapies
      • 8.2.2.3. Y-90 Based Therapies

9. Nuclear Medicine & Radiopharmaceuticals Market, by Isotope Type

  • 9.1. Cyclotron Produced Isotopes
    • 9.1.1. C-11
    • 9.1.2. F-18
  • 9.2. Generator Based Isotopes
    • 9.2.1. Ge-68 Ga-68 Generators
    • 9.2.2. Mo-99 Tc-99m Generators

10. Nuclear Medicine & Radiopharmaceuticals Market, by Application

  • 10.1. Bone Imaging
  • 10.2. Cardiology
  • 10.3. Inflammation Imaging
  • 10.4. Neurology
  • 10.5. Oncology

11. Nuclear Medicine & Radiopharmaceuticals Market, by End User

  • 11.1. Ambulatory Care Facilities
  • 11.2. Diagnostic Imaging Centers
  • 11.3. Hospital Radiology Departments
  • 11.4. Research Organizations

12. Nuclear Medicine & Radiopharmaceuticals Market, by Distribution Channel

  • 12.1. Offline
  • 12.2. Online

13. Nuclear Medicine & Radiopharmaceuticals Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Nuclear Medicine & Radiopharmaceuticals Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Nuclear Medicine & Radiopharmaceuticals Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Nuclear Medicine & Radiopharmaceuticals Market

17. China Nuclear Medicine & Radiopharmaceuticals Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Advanced Accelerator Applications S.A.
  • 18.6. AstraZeneca PLC
  • 18.7. Bayer AG
  • 18.8. Bracco Imaging S.p.A.
  • 18.9. Bristol-Myers Squibb Company
  • 18.10. BWX Technologies, Inc.
  • 18.11. Cardinal Health, Inc.
  • 18.12. Clarity Pharmaceuticals Ltd.
  • 18.13. Curium Pharma
  • 18.14. Eckert & Ziegler SE
  • 18.15. Eli Lilly and Company
  • 18.16. GE HealthCare Technologies Inc.
  • 18.17. Ion Beam Applications S.A.
  • 18.18. ITM Isotope Technologies Munich SE
  • 18.19. Jubilant Pharmova Limited
  • 18.20. Lantheus Holdings, Inc.
  • 18.21. NorthStar Medical Radioisotopes, LLC
  • 18.22. Novartis AG
  • 18.23. Siemens Healthineers AG
  • 18.24. Telix Pharmaceuticals Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY ISOTOPE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY PET RADIOPHARMACEUTICALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY PET RADIOPHARMACEUTICALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY PET RADIOPHARMACEUTICALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY PET RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY F-18 RADIOPHARMACEUTICALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY F-18 RADIOPHARMACEUTICALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY F-18 RADIOPHARMACEUTICALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY GA-68 RADIOPHARMACEUTICALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY GA-68 RADIOPHARMACEUTICALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY GA-68 RADIOPHARMACEUTICALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY NON TC-99M RADIOPHARMACEUTICALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY NON TC-99M RADIOPHARMACEUTICALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY NON TC-99M RADIOPHARMACEUTICALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY TC-99M RADIOPHARMACEUTICALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY TC-99M RADIOPHARMACEUTICALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY TC-99M RADIOPHARMACEUTICALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC RADIOPHARMACEUTICALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC RADIOPHARMACEUTICALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC RADIOPHARMACEUTICALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY ALPHA EMITTING RADIOPHARMACEUTICALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY ALPHA EMITTING RADIOPHARMACEUTICALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY ALPHA EMITTING RADIOPHARMACEUTICALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY BETA EMITTING RADIOPHARMACEUTICALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY BETA EMITTING RADIOPHARMACEUTICALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY BETA EMITTING RADIOPHARMACEUTICALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY BETA EMITTING RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY I-131 BASED THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY I-131 BASED THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY I-131 BASED THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY LU-177 BASED THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY LU-177 BASED THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY LU-177 BASED THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY Y-90 BASED THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY Y-90 BASED THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY Y-90 BASED THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY ISOTOPE TYPE, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY CYCLOTRON PRODUCED ISOTOPES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY CYCLOTRON PRODUCED ISOTOPES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY CYCLOTRON PRODUCED ISOTOPES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY CYCLOTRON PRODUCED ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY C-11, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY C-11, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY C-11, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY F-18, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY F-18, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY F-18, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY GENERATOR BASED ISOTOPES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY GENERATOR BASED ISOTOPES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY GENERATOR BASED ISOTOPES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY GENERATOR BASED ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY GE-68 GA-68 GENERATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY GE-68 GA-68 GENERATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY GE-68 GA-68 GENERATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY MO-99 TC-99M GENERATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY MO-99 TC-99M GENERATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY MO-99 TC-99M GENERATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY BONE IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY BONE IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY BONE IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY CARDIOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY CARDIOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY INFLAMMATION IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY INFLAMMATION IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY INFLAMMATION IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY AMBULATORY CARE FACILITIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY AMBULATORY CARE FACILITIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY AMBULATORY CARE FACILITIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY HOSPITAL RADIOLOGY DEPARTMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY HOSPITAL RADIOLOGY DEPARTMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY HOSPITAL RADIOLOGY DEPARTMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY PET RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY BETA EMITTING RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY ISOTOPE TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY CYCLOTRON PRODUCED ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY GENERATOR BASED ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. AMERICAS NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY PET RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY BETA EMITTING RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY ISOTOPE TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY CYCLOTRON PRODUCED ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY GENERATOR BASED ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY PET RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY BETA EMITTING RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY ISOTOPE TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY CYCLOTRON PRODUCED ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY GENERATOR BASED ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 142. LATIN AMERICA NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY PET RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY BETA EMITTING RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY ISOTOPE TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY CYCLOTRON PRODUCED ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY GENERATOR BASED ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY PET RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY BETA EMITTING RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY ISOTOPE TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY CYCLOTRON PRODUCED ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY GENERATOR BASED ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. MIDDLE EAST NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY PET RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 174. MIDDLE EAST NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 175. MIDDLE EAST NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY BETA EMITTING RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY ISOTOPE TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. MIDDLE EAST NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY CYCLOTRON PRODUCED ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY GENERATOR BASED ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 180. MIDDLE EAST NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. MIDDLE EAST NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 183. AFRICA NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. AFRICA NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. AFRICA NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 186. AFRICA NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY PET RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 187. AFRICA NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 188. AFRICA NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 189. AFRICA NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY BETA EMITTING RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 190. AFRICA NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY ISOTOPE TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. AFRICA NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY CYCLOTRON PRODUCED ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 192. AFRICA NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY GENERATOR BASED ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 193. AFRICA NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 194. AFRICA NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 195. AFRICA NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 196. ASIA-PACIFIC NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 197. ASIA-PACIFIC NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. ASIA-PACIFIC NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 199. ASIA-PACIFIC NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY PET RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 200. ASIA-PACIFIC NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 201. ASIA-PACIFIC NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 202. ASIA-PACIFIC NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY BETA EMITTING RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 203. ASIA-PACIFIC NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY ISOTOPE TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. ASIA-PACIFIC NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY CYCLOTRON PRODUCED ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 205. ASIA-PACIFIC NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY GENERATOR BASED ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 206. ASIA-PACIFIC NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 207. ASIA-PACIFIC NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 208. ASIA-PACIFIC NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 209. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 210. ASEAN NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. ASEAN NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. ASEAN NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 213. ASEAN NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY PET RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 214. ASEAN NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 215. ASEAN NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 216. ASEAN NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY BETA EMITTING RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 217. ASEAN NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY ISOTOPE TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. ASEAN NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY CYCLOTRON PRODUCED ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 219. ASEAN NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY GENERATOR BASED ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 220. ASEAN NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 221. ASEAN NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 222. ASEAN NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 223. GCC NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 224. GCC NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. GCC NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 226. GCC NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY PET RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 227. GCC NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 228. GCC NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 229. GCC NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY BETA EMITTING RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 230. GCC NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY ISOTOPE TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. GCC NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY CYCLOTRON PRODUCED ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 232. GCC NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY GENERATOR BASED ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 233. GCC NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 234. GCC NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 235. GCC NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPEAN UNION NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPEAN UNION NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPEAN UNION NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPEAN UNION NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY PET RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPEAN UNION NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPEAN UNION NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPEAN UNION NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY BETA EMITTING RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPEAN UNION NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY ISOTOPE TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPEAN UNION NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY CYCLOTRON PRODUCED ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPEAN UNION NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY GENERATOR BASED ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPEAN UNION NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPEAN UNION NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPEAN UNION NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 249. BRICS NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 250. BRICS NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 251. BRICS NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 252. BRICS NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY PET RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 253. BRICS NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 254. BRICS NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 255. BRICS NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY BETA EMITTING RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 256. BRICS NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY ISOTOPE TYPE, 2018-2032 (USD MILLION)
  • TABLE 257. BRICS NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY CYCLOTRON PRODUCED ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 258. BRICS NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY GENERATOR BASED ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 259. BRICS NUCLEAR MEDICINE & RADIOPHARMACEUTICA